Mr. Speaker, I am in fact very sensitive to the arguments put forward by my colleague. I agree that there should be a debate on this topic.
When we speak of patents, we are speaking of patents on drugs, on biotechnology research. It is still for the common good. There are people who invest in research and development, still for the common good.
But when it comes to the human genome, serious philosophical questions arise, as my colleague pointed out. We are therefore going to let the committee do its work and then the government can take another look at this.